CN118146306A - 基质金属蛋白酶底物和其它可切割部分及其使用方法 - Google Patents
基质金属蛋白酶底物和其它可切割部分及其使用方法 Download PDFInfo
- Publication number
- CN118146306A CN118146306A CN202410265536.XA CN202410265536A CN118146306A CN 118146306 A CN118146306 A CN 118146306A CN 202410265536 A CN202410265536 A CN 202410265536A CN 118146306 A CN118146306 A CN 118146306A
- Authority
- CN
- China
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- activatable antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361882377P | 2013-09-25 | 2013-09-25 | |
| US61/882377 | 2013-09-25 | ||
| US201461971332P | 2014-03-27 | 2014-03-27 | |
| US61/971332 | 2014-03-27 | ||
| CN201480064185.0A CN106163556B (zh) | 2013-09-25 | 2014-09-25 | 基质金属蛋白酶底物和其它可切割部分及其使用方法 |
| PCT/US2014/057523 WO2015048329A2 (en) | 2013-09-25 | 2014-09-25 | Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480064185.0A Division CN106163556B (zh) | 2013-09-25 | 2014-09-25 | 基质金属蛋白酶底物和其它可切割部分及其使用方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118146306A true CN118146306A (zh) | 2024-06-07 |
Family
ID=51691175
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480064185.0A Active CN106163556B (zh) | 2013-09-25 | 2014-09-25 | 基质金属蛋白酶底物和其它可切割部分及其使用方法 |
| CN202410265535.5A Pending CN118165076A (zh) | 2013-09-25 | 2014-09-25 | 基质金属蛋白酶底物和其它可切割部分及其使用方法 |
| CN202410265536.XA Pending CN118146306A (zh) | 2013-09-25 | 2014-09-25 | 基质金属蛋白酶底物和其它可切割部分及其使用方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480064185.0A Active CN106163556B (zh) | 2013-09-25 | 2014-09-25 | 基质金属蛋白酶底物和其它可切割部分及其使用方法 |
| CN202410265535.5A Pending CN118165076A (zh) | 2013-09-25 | 2014-09-25 | 基质金属蛋白酶底物和其它可切割部分及其使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20150087810A1 (enExample) |
| EP (1) | EP3049111A2 (enExample) |
| JP (5) | JP6915987B2 (enExample) |
| KR (3) | KR20250051130A (enExample) |
| CN (3) | CN106163556B (enExample) |
| AU (3) | AU2014324884B2 (enExample) |
| CA (2) | CA3214529A1 (enExample) |
| IL (3) | IL322893A (enExample) |
| MX (2) | MX379106B (enExample) |
| NZ (2) | NZ756892A (enExample) |
| RU (1) | RU2715232C2 (enExample) |
| WO (1) | WO2015048329A2 (enExample) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| EA035322B1 (ru) | 2013-05-28 | 2020-05-28 | ДиЭсБи-ЮЭсЭй ЛЛК | Антитело с "запирающими" свойствами для инактивации лекарства белкового происхождения |
| US20150087810A1 (en) | 2013-09-25 | 2015-03-26 | Cytomx Therapeutics, Inc. | Matrix Metalloproteinase Substrates And Other Cleavable Moieties And Methods Of Use Thereof |
| EP3628328B1 (en) | 2014-01-31 | 2022-09-14 | Cytomx Therapeutics Inc. | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
| BR112017008575B1 (pt) | 2014-10-29 | 2021-07-13 | Bicyclerd Limited | Ligantes de peptídeos bicíclicos específicos a mt1-mmp, conjugado de fármaco, processo para preparação de um conjugado de fármaco e composição farmacêutica |
| MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| IL303905A (en) | 2015-05-18 | 2023-08-01 | Tcr2 Therapeutics Inc | Compositions and methods for TCR programming using fusion proteins |
| SG10202101909RA (en) | 2015-08-07 | 2021-04-29 | Alx Oncology Inc | Constructs having a sirp-alpha domain or variant thereof |
| CN106519037B (zh) * | 2015-09-11 | 2019-07-23 | 科济生物医药（上海）有限公司 | 可活化的嵌合受体 |
| WO2017087789A1 (en) | 2015-11-19 | 2017-05-26 | Revitope Limited | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| EP3389720A1 (en) | 2015-12-18 | 2018-10-24 | The General Hospital Corporation | Polyacetal polymers, conjugates, particles and uses thereof |
| JP7185530B2 (ja) | 2016-06-13 | 2022-12-07 | トルク セラピューティクス， インコーポレイテッド | 免疫細胞機能を促進するための方法および組成物 |
| TW202323287A (zh) | 2016-11-28 | 2023-06-16 | 日商中外製藥股份有限公司 | 包含抗原結合域與運送部分的多胜肽 |
| KR20230073346A (ko) | 2016-11-28 | 2023-05-25 | 추가이 세이야쿠 가부시키가이샤 | 리간드 결합 활성을 조정 가능한 리간드 결합 분자 |
| WO2018106738A1 (en) | 2016-12-05 | 2018-06-14 | Massachusetts Institute Of Technology | Brush-arm star polymers, conjugates and particles, and uses thereof |
| EP3551667A4 (en) | 2016-12-09 | 2020-06-17 | Seattle Genetics, Inc. | Bivalent antibodies masked by coiled coils |
| KR20240165484A (ko) | 2017-04-11 | 2024-11-22 | 인히브릭스 바이오사이언스, 인크. | 제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 이를 이용한 방법 |
| EP3625253A4 (en) * | 2017-05-16 | 2021-03-24 | Scalmibio, Inc. | ACTIVABLE ANTIBODIES AND THEIR METHODS OF USE |
| CN107501394B (zh) * | 2017-06-19 | 2021-02-26 | 天津医科大学 | 高特异性mmp-14底物肽及其制备方法和应用 |
| CN118772242A (zh) | 2017-08-04 | 2024-10-15 | 拜斯科技术开发有限公司 | Cd137特异性的双环肽配体 |
| KR20200040819A (ko) | 2017-08-16 | 2020-04-20 | 브리스톨-마이어스 스큅 컴퍼니 | 항체를 표적화하기 위한 항 ctla-4 프로바디 치료제 |
| WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | Anti-cd137 molecules and use thereof |
| MX2020005160A (es) | 2017-11-28 | 2020-08-20 | Chugai Pharmaceutical Co Ltd | Molecula de union a ligando que tiene actividad de union a ligando ajustable. |
| WO2019107380A1 (ja) | 2017-11-28 | 2019-06-06 | 中外製薬株式会社 | 抗原結合ドメインおよび運搬部分を含むポリペプチド |
| EA202091339A1 (ru) | 2017-12-01 | 2020-10-21 | Сиэтл Дженетикс, Инк. | Антитела против cd47 и их применение для лечения онкологических заболеваний |
| WO2019148445A1 (en) * | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| BR112020014576A2 (pt) | 2018-02-23 | 2020-12-08 | Bicycletx Limited | Ligantes peptídicos bicíclicos multiméricos |
| EP3769309A1 (en) | 2018-03-20 | 2021-01-27 | Cytomx Therapeutics Inc. | Systems and methods for quantitative pharmacological modeling of activatable antibody species in mammalian subjects |
| EP3773913A1 (en) | 2018-04-11 | 2021-02-17 | Inhibrx, Inc. | Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses |
| WO2019222275A2 (en) * | 2018-05-14 | 2019-11-21 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using inducible fusion proteins |
| SG11202011308VA (en) | 2018-05-14 | 2020-12-30 | Werewolf Therapeutics Inc | Activatable cytokine polypeptides and methods of use thereof |
| US20210130430A1 (en) * | 2018-05-14 | 2021-05-06 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| JP7460609B2 (ja) | 2018-05-14 | 2024-04-02 | ウェアウルフ セラピューティクス， インコーポレイテッド | 活性化可能なインターロイキン－２ポリペプチド及びその使用方法 |
| WO2019230868A1 (ja) | 2018-05-30 | 2019-12-05 | 中外製薬株式会社 | 単ドメイン抗体含有リガンド結合分子 |
| WO2019230866A1 (en) * | 2018-05-30 | 2019-12-05 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide comprising il-1r1 binding domain and carrying moiety |
| US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| US12195533B2 (en) | 2018-07-24 | 2025-01-14 | Inhibrx Biosciences, Inc. | Multispecific polypeptide constructs containing a constrained CD3 binding domain and a receptor binding region and methods of using the same |
| EP3837266A1 (en) | 2018-08-17 | 2021-06-23 | Massachusetts Institute of Technology | Degradable polymers of a cyclic silyl ether and uses thereof |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| EP3864049A1 (en) | 2018-10-11 | 2021-08-18 | Inhibrx, Inc. | Pd-1 single domain antibodies and therapeutic compositions thereof |
| JP2022512684A (ja) | 2018-10-11 | 2022-02-07 | インヒブルクス インコーポレイテッド | Ｂ７ｈ３シングルドメイン抗体およびその治療用組成物 |
| TWI863932B (zh) | 2018-10-11 | 2024-12-01 | 美商因荷布瑞克斯生物科學公司 | 5t4單域抗體及其治療性組合物 |
| TW202028245A (zh) | 2018-10-11 | 2020-08-01 | 美商英伊布里克斯公司 | Dll3單域抗體及其治療性組合物 |
| US12049505B2 (en) * | 2018-12-06 | 2024-07-30 | Cytomx Therapeutics, Inc. | Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| CN113474045A (zh) | 2018-12-21 | 2021-10-01 | 拜斯科技术开发有限公司 | Pd-l1特异性的双环肽配体 |
| TW202102270A (zh) | 2019-03-21 | 2021-01-16 | 美商伊繆諾金公司 | 製備細胞結合劑-藥物結合物之方法 |
| SG11202110922QA (en) | 2019-04-26 | 2021-10-28 | Immunogen Inc | Camptothecin derivatives |
| EP3969035A4 (en) * | 2019-05-14 | 2023-06-21 | Werewolf Therapeutics, Inc. | SEPARATION UNITS AND METHODS AND THEIR USE |
| US20210317143A9 (en) | 2019-05-20 | 2021-10-14 | Massachusetts Institute Of Technology | Boronic ester prodrugs and uses thereof |
| AU2020282791A1 (en) | 2019-05-31 | 2021-12-09 | ALX Oncology Inc. | Methods of treating cancer with SIRP alpha Fc fusion in combination with an immune checkpoint inhibitor |
| US20220233709A1 (en) | 2019-06-05 | 2022-07-28 | Seagen Inc. | Masked Antibody Formulations |
| BR112021023735A2 (pt) | 2019-06-05 | 2022-01-04 | Chugai Pharmaceutical Co Ltd | Molécula de ligação de sítio de clivagem de anti-corpo |
| WO2020247574A1 (en) | 2019-06-05 | 2020-12-10 | Seattle Genetics, Inc. | Methods of purifying masked antibodies |
| US20220251206A1 (en) | 2019-06-11 | 2022-08-11 | Bristol-Myers Squibb Company | Anti-ctla4 antibody prodruggable (probody) at a cdr position |
| TWI862640B (zh) | 2019-07-30 | 2024-11-21 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| MX2022005666A (es) | 2019-11-14 | 2022-10-07 | Werewolf Therapeutics Inc | Polipeptidos de citocina activables y metodos de uso de los mismos. |
| WO2021141662A1 (en) | 2020-01-10 | 2021-07-15 | Massachusetts Institute Of Technology | Proteolysis targeting chimeric molecules (protacs) with functional handles and uses thereof |
| CN114945597A (zh) * | 2020-01-17 | 2022-08-26 | 艾提欧生物疗法有限公司 | 降低脱靶毒性的前抗体 |
| IL294879A (en) | 2020-01-29 | 2022-09-01 | Inhibrx Inc | Cd28 single domain antibodies and multivalent and multispecific constructs thereof |
| AU2021254279A1 (en) | 2020-04-09 | 2022-11-10 | Cytomx Therapeutics, Inc. | Compositions containing activatable antibodies |
| JP2023520922A (ja) | 2020-04-10 | 2023-05-22 | シートムエックス セラピューティクス，インコーポレイテッド | 活性化可能サイトカイン構築物および関連組成物ならびに方法 |
| US20220031858A1 (en) | 2020-08-03 | 2022-02-03 | Bicycle TX Limited | Novel linkers |
| IL305335A (en) * | 2021-02-25 | 2023-10-01 | Allygen Group | Targeted conjugates containing activator molecules and their uses |
| TW202304958A (zh) | 2021-03-16 | 2023-02-01 | 美商Ｃｙｔｏｍｘ生物製藥公司 | 經遮蔽之可活化之細胞介素構築體及相關之組成物及方法 |
| EP4337190A1 (en) | 2021-05-13 | 2024-03-20 | ALX Oncology Inc. | Combination therapies for treating cancer |
| EP4370211A1 (en) | 2021-07-14 | 2024-05-22 | Seagen Inc. | Antibody masking domains |
| WO2023034825A1 (en) | 2021-08-30 | 2023-03-09 | Cytomx Therapeutics, Inc. | Method for determining protease activity in a biological sample |
| EP4405387A1 (en) | 2021-09-24 | 2024-07-31 | Seagen Inc. | Improved antibody masking domains |
| TW202334185A (zh) | 2021-10-08 | 2023-09-01 | 美商Ｃｙｔｏｍｘ生物製藥公司 | 可經活化之細胞介素構築體和組合方法 |
| WO2023060156A2 (en) | 2021-10-08 | 2023-04-13 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| WO2023064955A1 (en) | 2021-10-15 | 2023-04-20 | Cytomx Therapeutics, Inc. | Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex |
| KR20240118749A (ko) | 2021-10-15 | 2024-08-05 | 싸이톰스 테라퓨틱스, 인크. | 활성화 가능한 폴리펩타이드 복합체 |
| IL312145A (en) | 2021-10-15 | 2024-06-01 | Amgen Inc | An activatable polypeptide complex |
| EP4496816A1 (en) | 2022-03-23 | 2025-01-29 | CytomX Therapeutics, Inc. | Activatable antigen-binding protein constructs and uses of the same |
| CN119301151A (zh) | 2022-03-25 | 2025-01-10 | 西托姆克斯治疗公司 | 可激活双锚定掩蔽分子和其使用方法 |
| WO2024030858A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable substrates and methods of use thereof |
| EP4565690A1 (en) | 2022-08-01 | 2025-06-11 | CytomX Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
| AR130077A1 (es) | 2022-08-01 | 2024-10-30 | Cytomx Therapeutics Inc | Substratos escindibles por proteasas, y métodos de uso de los mismos |
| WO2024030845A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
| TW202424184A (zh) | 2022-08-01 | 2024-06-16 | 美商Ｃｙｔｏｍｘ生物製藥公司 | 蛋白酶可切割部分及其使用方法 |
| WO2024216194A1 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Masking polypeptides, activatable cytokine constructs, and related compositions and methods |
| CN120936384A (zh) | 2023-04-12 | 2025-11-11 | 西托姆克斯治疗公司 | 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法 |
| WO2024216170A2 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| WO2025038668A1 (en) | 2023-08-14 | 2025-02-20 | Voro Therapeutics, Inc. | Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof |
| WO2025082461A1 (zh) * | 2023-10-19 | 2025-04-24 | 优洛生物(上海)有限公司 | 多肽、生物活性偶联物及其制备方法和应用 |
| US20250296991A1 (en) | 2023-12-01 | 2025-09-25 | Ablynx N.V. | Precision activated polypeptides |
| WO2025235515A1 (en) | 2024-05-07 | 2025-11-13 | Cytomx Therapeutics, Inc. | Activatable polypeptide complex formulations |
| WO2025240659A2 (en) | 2024-05-14 | 2025-11-20 | Cytomx Therapeutics, Inc. | Activatable constructs, compositions and methods |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| WO1988001513A1 (fr) | 1986-08-28 | 1988-03-10 | Teijin Limited | Complexe d'anticorps cytocide et procede de production |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| PT752248E (pt) | 1992-11-13 | 2001-01-31 | Idec Pharma Corp | Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b |
| WO1997043423A2 (en) * | 1996-05-10 | 1997-11-20 | Danisco A/S | Alpha-glucuronidases of aspergillus, production thereof and their uses |
| AUPO930697A0 (en) * | 1997-09-19 | 1997-10-09 | Walter And Eliza Hall Institute Of Medical Research, The | Catalytic antibodies and a method of producing same |
| US6551795B1 (en) | 1998-02-18 | 2003-04-22 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics |
| CA2328422A1 (en) * | 1998-05-13 | 1999-11-18 | Diversys Limited | Selection system |
| CA2393002A1 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| US20110131679A2 (en) * | 2000-04-19 | 2011-06-02 | Thomas La Rosa | Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement |
| EP1286700A2 (en) | 2000-06-01 | 2003-03-05 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
| WO2002012475A2 (en) | 2000-08-04 | 2002-02-14 | Eli Lilly And Company | C1q-related factor, homologous polypeptides and therapeutic uses thereof |
| ES2368387T5 (es) | 2000-10-09 | 2019-03-07 | Cytomx Therapeutics Inc | Anticuerpos terapéuticos y que inducen tolerancia |
| US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
| AU2002230630A1 (en) | 2000-11-08 | 2002-05-21 | Beth Israel Deaconess Medical Center, Inc. | Methods for determining protease cleavage site motifs |
| US20050208602A1 (en) * | 2001-08-10 | 2005-09-22 | Rosen Craig A | 89 human secreted proteins |
| US7439319B2 (en) | 2001-09-14 | 2008-10-21 | Burnham Institute For Medical Research | Selective substrates for matrix metalloproteinases |
| WO2003038083A1 (en) | 2001-10-29 | 2003-05-08 | Bayer Healthcare Ag | Regulation of human type i adenylate cyclase |
| CN101044154A (zh) | 2002-02-14 | 2007-09-26 | 威廉·J·鲁特 | 治疗宿主中切割的嵌合分子 |
| US20040109855A1 (en) | 2002-07-23 | 2004-06-10 | Herman Waldmann | Therapeutic antibodies with reduced side effect |
| US8809504B2 (en) | 2002-09-03 | 2014-08-19 | Vit Lauermann | Inhibitor which is deactivatable by a reagent produced by a target cell |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| US9079936B2 (en) * | 2003-07-01 | 2015-07-14 | University Of Maryland, Baltimore | Derivatives of APF and methods of use |
| GB0417430D0 (en) | 2004-08-05 | 2004-09-08 | Uc3 | A novel HPV vaccine comprising peptides from host cell proteins |
| AU2006235276A1 (en) | 2005-04-07 | 2006-10-19 | Novartis Vaccines And Diagnostics Inc. | CACNA1E in cancer diagnosis, detection and treatment |
| EP1919931A4 (en) | 2005-08-31 | 2010-01-20 | Univ California | CELLULAR PEPTIDE SEQUENCE LIBRARIES (CLIPS) AND METHOD OF USE THEREOF |
| JP2009529522A (ja) | 2006-03-10 | 2009-08-20 | ディアト | 酵素で切断可能なリンカーを介して抗体に複合された抗癌剤 |
| MX2009003938A (es) * | 2006-10-27 | 2009-04-24 | Genentech Inc | Anticuerpos e inmunoconjugados y sus usos. |
| JP6035009B2 (ja) | 2007-08-22 | 2016-11-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用 |
| DE102008034659A1 (de) * | 2008-07-25 | 2010-02-04 | Schmidt-Seeger Gmbh | Rundbehälter zum Keimen oder Darren von Getreide |
| GB0819287D0 (en) | 2008-10-22 | 2008-11-26 | Univ Bradford | Compounds |
| WO2010077643A1 (en) * | 2008-12-08 | 2010-07-08 | Tegopharm Corporation | Masking ligands for reversible inhibition of multivalent compounds |
| US8895702B2 (en) | 2008-12-08 | 2014-11-25 | City Of Hope | Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies |
| EP3543256A1 (en) * | 2009-01-12 | 2019-09-25 | Cytomx Therapeutics Inc. | Modified antibody compositions, methods of making and using thereof |
| US9102925B2 (en) * | 2009-02-02 | 2015-08-11 | Washington State University | Compositions and methods for treating or preventing conditions and diseases associated with Mannheimia haemolytica |
| EP2398494A4 (en) | 2009-02-23 | 2015-10-28 | Cytomx Therapeutics Inc | Proproteins and their methods of use |
| US9309325B2 (en) | 2009-05-07 | 2016-04-12 | The Regents Of The University Of California | Antibodies and methods of use thereof |
| AU2010289692A1 (en) * | 2009-09-02 | 2012-04-19 | Kansas State University Research Foundation | MRI and optical assays for proteases |
| US8524220B1 (en) | 2010-02-09 | 2013-09-03 | David Gordon Bermudes | Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria |
| US20110214205A1 (en) * | 2010-02-26 | 2011-09-01 | Monsanto Technology Llc. | Isolated Novel Nucleic Acid and Protein Molecules from Foxtail Millet and Methods of Using Those Molecules to Generate Transgenic Plants with Enhanced Agronomic Traits |
| RU2561465C2 (ru) * | 2010-05-20 | 2015-08-27 | Аллерган, Инк. | Разрушаемые клостридиальные токсины |
| CN107903325B (zh) | 2011-05-16 | 2021-10-29 | 埃泰美德(香港)有限公司 | 多特异性fab融合蛋白及其使用方法 |
| DK2709667T3 (da) | 2011-05-16 | 2022-07-04 | Tagworks Pharmaceuticals B V | Bio-orthogonal lægemiddelaktivering |
| PE20150605A1 (es) | 2012-04-27 | 2015-05-28 | Cytomx Therapeutics Inc | Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico |
| WO2013192546A1 (en) | 2012-06-22 | 2013-12-27 | Cytomx Therapeutics, Inc. | Activatable antibodies having non-binding steric moieties and mehtods of using the same |
| BR112014031689A2 (pt) | 2012-06-22 | 2017-07-25 | Cytomx Therapeutics Inc | anticorpos reativos cruzados anti-jagged 1/jagged 2, anticorpos anti-jagged ativáveis e métodos de uso deles |
| EP2882844B1 (en) | 2012-08-10 | 2018-10-03 | Cytomx Therapeutics Inc. | Protease-resistant systems for polypeptide display and methods of making and using thereof |
| US9487590B2 (en) * | 2012-09-25 | 2016-11-08 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind interleukin-6 receptor and methods of use thereof |
| WO2014107559A1 (en) | 2013-01-03 | 2014-07-10 | Branders.Com, Inc. | Methods and apparatus for determining a score value for criteria associated with a gift |
| JP6605957B2 (ja) * | 2013-01-04 | 2019-11-13 | シトムクス セラピューティクス，インコーポレイティド | 生体系におけるプロテアーゼ活性を検出するための組成物及び方法 |
| WO2014176284A1 (en) | 2013-04-22 | 2014-10-30 | Avelas Biosciences, Inc. | Selective drug delivery compositions and methods of use |
| EA035322B1 (ru) | 2013-05-28 | 2020-05-28 | ДиЭсБи-ЮЭсЭй ЛЛК | Антитело с "запирающими" свойствами для инактивации лекарства белкового происхождения |
| US20150087810A1 (en) | 2013-09-25 | 2015-03-26 | Cytomx Therapeutics, Inc. | Matrix Metalloproteinase Substrates And Other Cleavable Moieties And Methods Of Use Thereof |
| EP3628328B1 (en) | 2014-01-31 | 2022-09-14 | Cytomx Therapeutics Inc. | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
| CA2955947A1 (en) | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| JP6826055B2 (ja) | 2015-03-13 | 2021-02-03 | サイトメックス セラピューティクス インコーポレイテッド | 抗ｐｄｌ１抗体、活性化可能抗ｐｄｌ１抗体、およびその使用方法 |
| HK1250037A1 (zh) | 2015-05-04 | 2018-11-23 | Cytomx Therapeutics Inc. | 抗-itga3抗体、可活化的抗-itga3抗体、及其使用方法 |
| MY194184A (en) | 2015-05-04 | 2022-11-17 | Cytomx Therapeutics Inc | Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof |
| JP7028648B2 (ja) | 2015-05-04 | 2022-03-02 | サイトメックス セラピューティクス インコーポレイテッド | 抗ｃｄ１６６抗体、活性化可能抗ｃｄ１６６抗体、およびその使用方法 |
| US10513558B2 (en) | 2015-07-13 | 2019-12-24 | Cytomx Therapeutics, Inc. | Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof |
| MY200695A (en) | 2016-11-03 | 2024-01-11 | Bristol Myers Squibb Co | Activatable anti-ctla-4 antibodies and uses thereof |
| JP2020511130A (ja) | 2017-03-09 | 2020-04-16 | サイトメックス セラピューティクス インコーポレイテッド | Ｃｄ１４７抗体、活性化可能ｃｄ１４７抗体、ならびにその作製および使用の方法 |
| BR112019025188A2 (pt) | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos |
| US12049505B2 (en) | 2018-12-06 | 2024-07-30 | Cytomx Therapeutics, Inc. | Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof |
-
2014
- 2014-09-25 US US14/497,089 patent/US20150087810A1/en not_active Abandoned
- 2014-09-25 IL IL322893A patent/IL322893A/en unknown
- 2014-09-25 WO PCT/US2014/057523 patent/WO2015048329A2/en not_active Ceased
- 2014-09-25 KR KR1020257010278A patent/KR20250051130A/ko active Pending
- 2014-09-25 JP JP2016516911A patent/JP6915987B2/ja active Active
- 2014-09-25 CN CN201480064185.0A patent/CN106163556B/zh active Active
- 2014-09-25 NZ NZ756892A patent/NZ756892A/en unknown
- 2014-09-25 CN CN202410265535.5A patent/CN118165076A/zh active Pending
- 2014-09-25 EP EP14783968.2A patent/EP3049111A2/en active Pending
- 2014-09-25 AU AU2014324884A patent/AU2014324884B2/en active Active
- 2014-09-25 NZ NZ718283A patent/NZ718283A/en unknown
- 2014-09-25 CN CN202410265536.XA patent/CN118146306A/zh active Pending
- 2014-09-25 MX MX2016003957A patent/MX379106B/es unknown
- 2014-09-25 IL IL291329A patent/IL291329B1/en unknown
- 2014-09-25 CA CA3214529A patent/CA3214529A1/en active Pending
- 2014-09-25 CA CA2925106A patent/CA2925106C/en active Active
- 2014-09-25 KR KR1020237000930A patent/KR102790260B1/ko active Active
- 2014-09-25 KR KR1020167010749A patent/KR102488220B1/ko active Active
- 2014-09-25 RU RU2016115542A patent/RU2715232C2/ru active
-
2016
- 2016-03-24 IL IL244744A patent/IL244744B/en unknown
- 2016-03-28 MX MX2021000416A patent/MX2021000416A/es unknown
-
2018
- 2018-11-02 US US16/179,670 patent/US11814410B2/en active Active
-
2019
- 2019-09-24 JP JP2019173550A patent/JP2020015749A/ja active Pending
-
2020
- 2020-06-12 AU AU2020203910A patent/AU2020203910B2/en active Active
-
2021
- 2021-05-10 JP JP2021080015A patent/JP2021138707A/ja not_active Withdrawn
-
2023
- 2023-07-27 JP JP2023122426A patent/JP2023159099A/ja active Pending
- 2023-09-25 US US18/474,103 patent/US20240150478A1/en active Pending
- 2023-09-25 US US18/474,134 patent/US20240084022A1/en active Pending
- 2023-10-25 AU AU2023254931A patent/AU2023254931A1/en active Pending
-
2024
- 2024-10-23 JP JP2024186751A patent/JP2025016554A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240150478A1 (en) | Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof | |
| US20240150402A1 (en) | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof | |
| US20240239904A1 (en) | Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof | |
| CN114685611B (zh) | 基质金属蛋白酶可切割且丝氨酸蛋白酶可切割底物及其使用方法 | |
| BR112016006665B1 (pt) | Polipeptídeo isolado que compreende uma região clivável (cm) que é um substrato de metaloproteinase de matriz, uso terapêutico do mesmo e método para detectar a presença ou ausência de um agente de clivagem e um alvo de interesse em uma amostra |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |